<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824224</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00015881</org_study_id>
    <nct_id>NCT02824224</nct_id>
  </id_info>
  <brief_title>Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)</brief_title>
  <official_title>Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the ability of tamoxifen to improve frequent or prolonged bleeding in
      new users of the 52mg levonorgestrel-releasing intrauterine device. Half of participants will
      receive a course of tamoxifen three weeks after insertion of the IUD, while the other half of
      participants will receive a course of placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New users of the LNG IUS will be eligible. Subjects will be randomized to receive tamoxifen
      10 mg BID for 7 days or placebo. Study drug will be started 3 weeks after placement of the
      IUS. Subjects will maintain a record of daily bleeding and spotting using an electronic text
      messaging diary.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in bleeding and spotting days</measure>
    <time_frame>30 days after initiation of study drug</time_frame>
    <description>Mean number of bleeding and spotting days in the tamoxifen group compared to the mean number of bleeding and spotting days in the placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding pattern satisfaction</measure>
    <time_frame>60 days after initiation of study drug</time_frame>
    <description>0-100 mm visual analog scale measurement of satisfaction with bleeding pattern</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IUD satisfaction</measure>
    <time_frame>60 days after initiation of study drug</time_frame>
    <description>0-100 mm visual analog scale measurement of satisfaction with IUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>60 days after initiation of study drug</time_frame>
    <description>Descriptive reporting of adverse events for each arm</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total number of bleeding/spotting episodes</measure>
    <time_frame>30 days after initiation of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of prolonged bleeding episodes (&gt;8 days)</measure>
    <time_frame>30 days after initiation of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Longest bleed-free interval</measure>
    <time_frame>30 days after initiation of study drug</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Menorrhagia</condition>
  <condition>Metrorrhagia</condition>
  <condition>Medicated Intrauterine Devices</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamoxifen 10mg tablet by mouth twice daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course</description>
    <arm_group_label>Tamoxifen</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Tamoxifen)</intervention_name>
    <description>Sugar pill manufactured to mimic the tamoxifen 10mg tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  initiating use of 52mg levonorgestrel-releasing IUD for contraceptive purposes

          -  access to reliable cell phone

          -  willing to receive and respond to daily text or email message to assess bleeding

        Exclusion Criteria:

          -  using IUD for indication other than contraception

          -  postpartum within 6 months, pregnant, or breastfeeding

          -  removal and replacement of IUD

          -  undiagnosed abnormal uterine bleeding prior to placement of IUD

          -  bleeding dyscrasia

          -  anti-coagulation use

          -  active cervicitis

          -  allergy to tamoxifen

          -  history of venous thromboembolism

          -  personal history of breast or uterine malignancy

          -  use of medication contraindicated with use of tamoxifen (coumadin, letrozole,
             bromocriptine, rifampicin, aminoglutethimide, phenobarbital)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Megan A Cohen, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Megan A Cohen, MD, MPH</last_name>
    <email>coheme@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeffrey Jensen, MD, MPH</last_name>
    <phone>503-494-2811</phone>
    <email>jensenje@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OHSU Center For Women's Health</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan A Cohen, MD, MPH</last_name>
      <email>coheme@ohsu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2016</study_first_submitted>
  <study_first_submitted_qc>July 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jeffrey Jensen</investigator_full_name>
    <investigator_title>Leon Speroff Professor of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>levonorgestrel</keyword>
  <keyword>breakthrough bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

